Deciphera Pharmaceuticals (DCPH)
(Delayed Data from NSDQ)
$14.18 USD
-0.44 (-3.01%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $14.20 +0.02 (0.14%) 7:46 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Company Summary
Headquartered in Waltham, Massachusetts, Deciphera Pharmaceuticals, Inc., develops small molecule kinase inhibitors for cancer, utilizing its proprietary kinase switch control inhibitor platform. In May 2020, 2020, the FDA approved Qinlock (ripretinib), for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including Gleevec (imatinib). This was the first commercial product for the company.
The drug was approved in Europe for the treatment of fourth-line GIST in November 2021. Qinlock is also approved in the United Kingdom, Switzerland, Canada, Australia, China, Taiwan and Hong Kong. In 2023, Qinlock ...
Company Summary
Headquartered in Waltham, Massachusetts, Deciphera Pharmaceuticals, Inc., develops small molecule kinase inhibitors for cancer, utilizing its proprietary kinase switch control inhibitor platform. In May 2020, 2020, the FDA approved Qinlock (ripretinib), for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including Gleevec (imatinib). This was the first commercial product for the company.
The drug was approved in Europe for the treatment of fourth-line GIST in November 2021. Qinlock is also approved in the United Kingdom, Switzerland, Canada, Australia, China, Taiwan and Hong Kong. In 2023, Qinlock generated sales worth $159.1 million.
The company is also working to expand the label of Qinlock for the larger commercial opportunity in second-line GIST.
In June 2019, the company granted Zai exclusive rights to develop and commercialize Qinlock, including certain follow-on compounds in Greater China. The company retains exclusive rights to develop, manufacture, and commercialize licensed products outside the territory.
The company is also working on expanding its portfolio beyond Qinlock. Deciphera is currently evaluating vimseltinib in a late-stage-study, for the treatment of tenosynovial giant cell tumor (TGCT). Furthermore, an early-to-mid-stage study is currently evaluating DCC-3116, a single agent and in combination studies, for the treatment of patients with advanced/metastatic tumors driven by mutations in RAS/RAF genes.
In 2023, Deciphera generated total revenues of $163.4 million, up 22% from $134 million recorded in 2022.
General Information
Deciphera Pharmaceuticals, Inc
200 SMITH STREET
Waltham, MA 02451
Phone: 781-209-6400
Fax: NA
Email: deciphera@argotpartners.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 5/1/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.55 |
Current Year EPS Consensus Estimate | -2.16 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 5/1/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 14.62 |
52 Week High | 17.73 |
52 Week Low | 9.90 |
Beta | 0.39 |
20 Day Moving Average | 456,898.94 |
Target Price Consensus | 25.89 |
4 Week | -3.69 |
12 Week | 2.10 |
YTD | -9.36 |
4 Week | -0.33 |
12 Week | -2.45 |
YTD | -14.76 |
Shares Outstanding (millions) | 80.80 |
Market Capitalization (millions) | 1,181.30 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 10.00% |
vs. Previous Quarter | 6.90% |
vs. Previous Year | 32.88% |
vs. Previous Quarter | 11.50% |
Price/Book | 3.34 |
Price/Cash Flow | NA |
Price / Sales | 7.23 |
3/31/24 | NA |
12/31/23 | -49.44 |
9/30/23 | -49.41 |
3/31/24 | NA |
12/31/23 | -38.41 |
9/30/23 | -38.53 |
3/31/24 | NA |
12/31/23 | 3.80 |
9/30/23 | 4.50 |
3/31/24 | NA |
12/31/23 | 3.59 |
9/30/23 | 4.20 |
3/31/24 | NA |
12/31/23 | -119.33 |
9/30/23 | -127.92 |
3/31/24 | NA |
12/31/23 | -119.33 |
9/30/23 | -127.92 |
3/31/24 | NA |
12/31/23 | -119.07 |
9/30/23 | -127.45 |
3/31/24 | NA |
12/31/23 | 4.38 |
9/30/23 | 4.76 |
3/31/24 | NA |
12/31/23 | 0.15 |
9/30/23 | 0.21 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |